Compare YEXT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YEXT | LYEL |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.0M | 320.1M |
| IPO Year | 2017 | 2021 |
| Metric | YEXT | LYEL |
|---|---|---|
| Price | $5.66 | $12.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $7.50 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 1.2M | 161.8K |
| Earning Date | 06-02-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.82 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $170,201,000.00 | $36,000.00 |
| Revenue This Year | $3.95 | N/A |
| Revenue Next Year | $2.46 | $8,712.13 |
| P/E Ratio | $276.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.27 | $9.28 |
| 52 Week High | $9.20 | $45.00 |
| Indicator | YEXT | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 68.33 | 44.30 |
| Support Level | $5.36 | $11.59 |
| Resistance Level | $5.69 | $14.14 |
| Average True Range (ATR) | 0.25 | 0.91 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 87.75 | 14.50 |
Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.